Venture Visionary Partners LLC Reduces Stock Holdings in Pfizer Inc. $PFE

Key Points

• Venture Visionary Partners LLC significantly reduced its stake in Pfizer by 51.5%, selling 204,375 shares and holding 192,771 shares valued at approximately $4.67 million.
• Several hedge funds modified their positions in Pfizer during the second quarter, and a total of 68.36% of the stock is currently owned by institutional investors.
• Analysts have mixed ratings for Pfizer, with a consensus rating of "Hold" and target prices ranging from $25 to $33, reflecting cautious sentiment regarding the stock's performance.

Venture Visionary Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 51.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 192,771 shares of the biopharmaceutical company's stock after selling 204,375 shares during the quarter. Venture Visionary Partners LLC's holdings in Pfizer were worth $4,673,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of PFE. Capital Advisory Group Advisory Services LLC increased its holdings in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after purchasing an additional 388 shares during the last quarter. Trust Co of the South grew its position in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after acquiring an additional 441 shares in the last quarter. Charter Oak Capital Management LLC grew its position in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after acquiring an additional 444 shares in the last quarter. Ballentine Partners LLC grew its position in shares of Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after acquiring an additional 458 shares in the last quarter. Finally, Members Trust Co grew its position in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

Shares of PFE stock opened at $23.84 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock's 50-day moving average is $24.54 and its two-hundred day moving average is $24.11. The firm has a market cap of $135.54 billion, a P/E ratio of 12.68, a PEG ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.